Related Experiment Video
Updated: Jul 10, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
The potential of targeting Toll-like receptor 2 in autoimmune and inflammatory diseases
E M Pålsson-McDermott1, L A J O'Neill
1School of Biochemistry and Immunology, Trinity College, Dublin, Ireland. palssone@tcd.ie
Abstract:
The last decade has revealed interesting insights into the initiation and pathophysiology of the innate immune system. Toll-like receptors are of key importance for this process and they are a family of receptors expressed mainly on leukocytes that recognize a variety of microbial products derived from bacteria, viruses, protozoa and fungi. As key players of innate immunity, TLRs and downstream signalling components are important target candidates for drug development. In this review, we focus on TLR2, which recognizes bacterial lipopeptide. TLR2 forms dimers with TLR1 or TLR6. The TLR2/TLR1 dimer recognizes triacylated lipopeptides, whilst the TLR2/TLR6 dimer recognizes diacylated lipopeptides. TLR2 has been implicated in several auto-immune and inflammatory conditions, and its role in disease pathogenesis has been supported by numerous reports of TLR2 polymorphisms in humans linked to disease. Here we discuss the potential of TLR2 as a drug target in autoimmune and inflammatory disease.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease III: Crohn's Disease
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
The JAK-STAT Signaling Pathway
